CD274 and breast carcinoma: According to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) [6], combination therapy with pembrolizumab is recommended as the first-line treatment in patients with PD-L1-positive mTNBC regardless of germline breast cancer susceptibility gene (BRCA) mutation status.